O RLANDO, Fla. — Researchers presented early-phase trial results on RLY-2608, Relay Therapeutics’ next-generation PI3K inhibitor, at the American Association for Cancer Research annual meeting ...

RLY-2608 preferentially binds mutant PI3Kα at a novel allosteric site discovered by the Dynamo™ platform Preclinically, achieved tumor regressions in vivo with significantly reduced impact on ...

Potential Positives. Updated interim clinical data for RLY-2608 show a median progression free survival (PFS) of 11.0 months in second line (2L) patients with PI3Kα-mutated, HR+, HER2- metastatic ...

We are encouraged by the consistency of these updated RLY-2608 + fulvestrant data, which continue to show the potential benefit of a mutant-selective PI3Kα inhibitor for improving both the ...